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Objective
Patients with Prader-Willi syndrome (PWS) is known to
have bone fragility. Osteoporosis may be associated with
bone fractures and poor surgical outcome for scoliosis.
Current growth hormone (GH) treatment offers a viable
and safe means to reduce these risks by improving bone
density. The purposes of this study were to investigate
bone mineral density (BMD) with PWS patients and to
verify efficacy of growth hormone (GH) administration
for osteoporosis.
Methods
We investigated 148 patients (91 male, 57 females) with
PWS who examined BMD and followed for at least
2 years at our out-patient clinic. Measurement was taken
at the lumbar spine (L2-4). The mean age was 9.35 (2-47)
years at initial BMD. Scoliosis was found in 64 PWS
patients (GH plus, 45; minus, 19). Mean cobb angle was
30.6 (range 12-88) degrees. There were 84 non-scoliosis
patients (GH plus; 51, GH minus; 33). Patients were trea-
ted with GH (0.245 mg/kg/week) over a period of 3 to 16
years (mean, 5 years, 11 months). We also evaluated the
effect of GH treatment on BMD in 108 patients who
underwent BMD testing more than twice (GH plus, 89
patients; GH minus, 19 patients).
We focused on the following:
1) Measuring the lumbar BMD before GH treatment
and evaluated the prevalence of bone fragility (osteo-
porosis and osteopenia) in all patients.
2) Retrospectively evaluating the association between
scoliosis and lumbar BMD.
3) Comparing the BMD between at initial and at
final follow-up stage to determine the effect of GH
treatment for the increase of BMD.
Results
1). Total lumbar BMD (L2-4) was 0.567 g/cm
(Z score -2.12). Fifty (33.8%) patients had osteoporosis
(Z score <-2.5) and 41 (27.7%) patients had osteopenia
(-1.5< Z score<-2.5). Total 61.5% of patients showed
bone fragility (osteoporosis and osteopenia).
2). The scoliosis group was 0.598 g/cm (Z score -2.08)
and non-scoliosis group was 0.548 g/cm (Z score -2.27).
There were no significant differences between the two
Groups (P=0.075).
3). GH treatment revealed a significant increase of L2-4
BMD (GH plus; 7.95%VS GH minus: 2.57%, P<0.01).
Conclusions
1) 61.5 % of patients with PWS had bone fragility.
2) The frequency of scoliosis was not correlated with
BMD.3) GH administration significantly improved BMD.
GH therapy may be a useful treatment for reducing the
frequency of bone fractures and surgical risk in PWS
patients associated with osteoporosis.
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